Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
1. A method of treating juvenile idiopathic arthritis (JIA) in a patient comprising subcutaneously administering an anti-IL-6 receptor (IL-6R) antibody to the patient in an amount effective to treat the JIA, wherein the anti-IL-6R antibody is administered as a fixed dose of 162 mg per dose every week, every two weeks, or every three weeks, and wherein the anti-IL-6R antibody comprises the light chain and heavy chain amino acid sequences of SEQ ID NOs: 1 and 2, respectively.
2. The method of claim 1 wherein the JIA is systemic JIA (sJIA).
3. The method of claim 2 wherein the fixed dose is administered every week if the patient's weight is ≥30 kilograms.
4. The method of claim 2 wherein the fixed dose is administered every two weeks if the patient's weight is <30 kilograms.
5. The method of claim 1 wherein the JIA is polyarticular course juvenile idiopathic arthritis (pcJIA).
6. The method of claim 5 wherein the fixed dose is administered every two weeks if the patient's weight is ≥30 kilograms.
7. The method of claim 5 wherein the fixed dose is administered every three weeks if the patient's weight is <30 kilograms.
8. A method of treating juvenile idiopathic arthritis (JIA) in a patient comprising subcutaneously administering tocilizumab to the patient, wherein the tocilizumab is administered subcutaneously as a fixed dose of 162 mg per dose every week, every two weeks, or every three weeks.
9. The method of claim 8 wherein the JIA is systemic JIA (sJIA).
10. The method of claim 9 wherein the tocilizumab is administered every week if the patient's weight is ≥30 kilograms.
11. The method of claim 9 wherein the tocilizumab is administered every two weeks if the patient's weight is <30 kilograms.
12. The method of claim 8 wherein the JIA is polyarticular course juvenile idiopathic arthritis (pcJIA).
13. The method of claim 12 wherein the tocilizumab is administered every two weeks if the patient's weight is ≥30 kilograms.
14. The method of claim 12 wherein the tocilizumab is administered every three weeks if the patient's weight is <30 kilograms.